previou work cellular prion protein prpc identifi upregul gene adriamycin-resist gastric carcinoma cell line sgc7901/adr compar parent cell line sgc7901 here investig express prpc gastric cancer whether involv multidrug resist mdr gastric cancer demonstr prpc ubiquit express gastric cancer cell line tissu prpc confer resist both p-glycoprotein p-gp -relat p-gp-nonrel drug sgc7901 accompani decreas accumul increas releas amount adriamycin prpc-overexpress cell line inhibit prpc express antisens rnai technolog partial revers multidrug-resist phenotyp sgc7901/adr prpc significantli upregul express classic mdr-relat molecul p-gp multidrug resist associ protein glutathion s-transferas prpc-induc mdr partial revers p-gp inhibitor verapamil prpc suppress adriamycin-induc apoptosi alter express bcl-2 bax anoth pathwai contribut prpc-relat mdr studi biolog function prpc help understand mechan occurr develop clinic gastric carcinoma prpc-relat mdr develop possibl strategi treat gastric cancer
previou studi suggest lack runx3 function causal relat genesi progress human gastric cancer potenti role member runx famili gene yet report examin express runt-relat runx gene runx1 runx2 cbfb gastric cancer cell line primari gastric cancer specimen compar runx3 report earlier conjunct clinicopatholog factor express runx famili gene gastric cancer cell line primari gastric cancer specimen surround normal gastric mucosa estim northern blot analysi quantit rt-pcr situ hybrid northern blot analysi gastric cancer cell line show downregul runx1 runx3 cell line test respect ratio averag runx mrna/beta-actin mrna ratio x10 runx1 48.0 +/- 21.1 21.4 +/- 8.1 runx2 1.1 +/- 0.3 1.0 +/- 0.2 runx3 9.2 +/- 6.3 3.1 +/- 1.3 cbfb 42.0 +/- 19.4 21.0 +/- 8.4 normal tumor respect averag +/-sd basal runx2 express weak signific chang gastric cancer both runx1 runx3 show remark downregul respect surgic resect specimen compar surround mucosa analyz quantit rt-pcr &lt 0.01 furthermor cbfb gene encod cofactor runx1 downregul signific fraction &lt 0.05 percentag downregul runx1 runx3 cbfb increas cancer stage progress tricostatin 5'-azacitidin reactiv runx3 express reactiv express runx1 cbfbeta gastric cancer cell suggest downregul due mechan methyl promot region find suggest runx1 cbfbeta addit runx3 plai role gastric cancer role runx gene famili gastric cancer widespread complex previous realiz
degre chromosom loss presenc microsatellit instabl msi gastric carcinoma categor low-risk low-level loss msi high-risk baselin- high-level loss genotyp aim make preoper diagnosi studi confirm stem line genotyp common entir tumor well singl biopsi specimen biopsi specimen obtain gastric carcinoma patient examin microsatellit genotyp us panel microsatellit marker cancer-associ chromosom genotyp biopsi specimen compar surgic specimen multifoc examin intratumor heterogen pair biopsi surgic specimen contain same case similar case number chromosom loss categor same microsatellit genotyp remain pair classifi differ genotyp surgic specimen show extraseros invas lymph node metastasi frequent associ high-level chromosom loss irrespect tumor size larg carcinoma diamet irrespect tumor genotyp statu extraseros invas lymph node metastasi 0.691 0.802 receiv oper characterist area respect predict biopsi genotyp tumor size correspond close surgic patholog result extent chromosom loss presenc msi determin biopsi specimen will provid valuabl inform make preoper genet diagnosi gastric carcinoma
purpos 1991 1994 perform phase studi intens preoper chemoradi local advanc squamou cell carcinoma adenocarcinoma esophagu report multivari analysi prognost factor base long-term result median follow-up 6.5 year patient method eighti-eight patient treat prognost factor overal surviv local tumor control identifi univari multivari analysi result median overal surviv reach month surviv rate year -confid interv 18-26 respons induct chemotherapi independ factor predict local tumor control and--besid weight loss prior treatment--it prove independ prognost factor long-term surviv conclus intens chemoradi follow surgeri seem appropri improv long-term surviv high-risk patient local advanc esophag cancer trial local tumor control prognosi best correl respons induct chemotherapi result help guid decis regard surgeri multimod treatment effort need increas number treatment respond predict tumor respond chemo radio therapi earlier
purpos matrix metalloproteinas-9 mmp-9 gelatinas plai kei role cancer invas metastasi degrad extracellular matrix ecm basement membran barrier cytosin -thymidin singl nucleotid polymorph snp posit -1562 mmp-9 promot report affect express gene purpos studi investig relat -1562 c/t polymorph develop progress gastric cancer method studi popul includ 177 gastric cancer patient 224 healthi control subject snp mmp-9 promot analyz polymeras chain reaction-restrict fragment length polymorph pcr-rflp sequenc genotyp frequenc compar patient control associ genotyp clinicopatholog featur studi result genotyp frequenc gastric cancer patient similar control subject 0.223 howev signific associ found degre tumor invas clinic stage lymphat invas mmp-9 polymorph gastric cancer patient p&lt 0.05 conclus result indic allel mmp-9 promot associ invas phenotyp gastric cancer
adam disintegrin metalloproteinas famili cell-surfac membran glycoprotein multidomain structur enabl divers role wide rang cellular process accumul evid associ increas express individu adam famili member variou type cancer investig possibl involv adam9 pathogenesi gastric cancer us immunohistochemistri quantit rt-pcr examin transcript express pattern adam9 gc correspond non-tumor tissu cell line ag mkn45 mkn28 nci-n87 katoiii three adam found significantli upregul compar non-neoplast foveolar epithelium adam12 express higher intestin- diffus-type tumor vitro prolifer assai us evalu effect adam-specif antibodi growth cell line administr anti-adam9 anti-adam15 antibodi inhibit cell growth wherea anti-adam12 enhanc prolifer cell line adam9 implic malign growth cell via interact adhes molecul proteolyt 'shed' signal molecul consequ transactiv receptor epitheli growth factor receptor ligand result modul tumor-host interfac contribut pathogenesi develop progress gastric cancer
purpos review gastric carcinoid tumor rare lesion focu much scientif investig incid gastric carcinoid appear increas correspond increas surviv despit util latest avail therapi great interest further understand biolog basi tumor delin connect hypergastrinemia gastric carcinoid most importantli improv current treatment option recent find review discuss current biolog understand gastric carcinoid tumor includ role hypergastrinemia enterochromaffin-like cell prolifer relat acid-suppress therapi numer diagnost therapeut modal includ endoscop ultrasound somatostatin receptor scintigraphi long-act octreotid hepat arteri embol endoscop mucos resect surgic resect focu recent investig summari despit advanc made both basic scienc clinic arena optim treatment gastric carcinoid tumor still matter debat understand biolog basi gastric carcinoid tumor increas treatment will like multimod approach tailor individu tumor biologi will incorpor varieti diagnost therapeut modal
aim determin dose-limit toxic dlt maximum toler dose mtd recommend dose oxaliplatin combin oral tegafur-uracil leucovorin twenti-eight chemo-naiv patient advanc gastric cancer enrol oxaliplatin 100 115 mg/m2 given 2-h infus dai oral tegafur-uracil 300 mg/m2 per dai leucovorin mg/dai given time dai dai 28-dai cycl dlt defin grade hematolog toxic grade iii non-hematolog toxic mtd oxaliplatin 100 mg/m2 most common dlt diarrhea major grade iii/iv toxic includ vomit diarrhea renal dysfunct leukopenia thrombocytopenia two treatment-relat death intent-to-treat respons grade partial respons patient 46.4 confid interv 26.74-66.12 stabl diseas nine diseas progress five june 2004 patient di median time treatment failur time progress overal surviv 124 308 434 dai respect recommend dose phase studi oxaliplatin 100 mg/m2 biweekli oral tegafur-uracil 300 mg/m2 per dai leucovorin mg/dai time dai dai
individu respons dissemin cancer chemotherapi unpredict vitro chemotherapi-induc apoptosi measur method evalu vivo activ test drug report tumor cell patient signet cell carcinoma stomach diffus bone marrow infiltr cultur test vitro chemosensit drug gemcitabin oxaliplatin zoledron acid found induc vitro tumor cell apoptosi synergist subsequ us combin chemotherapi regimen initi exist dissemin intravascular coagulopathi quickli resolv month treatment ongo complet respons induc confirm result vitro chemosensit test
efficaci suicid gene therapi us herp simplex viru thymidin kinas/ganciclovir hsvtk/gcv system treatment cancer limit becaus insuffici gene transfer low kill activ enhanc antitumor activ probe whether recombin ritrovir express vector plxsn express both hsvtk tnf-alpha gene potenti destruct sgc7901 tk-tnf-alpha harbor hsvtk tnf-alpha gene sequenc construct bicistron unit includ intern ribosom entri site recombin retrovirus transfer sgc7901 cell lipofectamin pegfp western blot analysi us detect express fusion gene transfect sgc7901 cell apoptosi transfect cell detect us tdt-mediat dutp nick label flow cytometr analysi transmiss electron microscopi vitro studi transfect gastric cancer cell maintain gcv-contain medium assai cell kill effect bystand effect vivo experi retrovir serum plasmid transfect tumor-bear nude mice observ chang tumor volum surviv mice vitro signific differ cell surviv rate three group howev vivo result show tk/gcv tk-tnf-alpha/gcv tnf-alpha inhibit tumor growth obviou anti-tumor effect shown tk-tnf-alpha/gcv group tnf-alpha obvious enhanc anti-tumor effect vivo patholog examin show necrosi cancer treat group
object invas metastasi carcinoma cell requir proteolyt degrad extracellular matrix variou cell surfac proteas among sepras type transmembran serin proteas absent normal tissu implic invas extracellular matrix both tumor stromal cell human breast carcinoma melanoma present studi express sepras mrna protein gelatin-degrad activ human gastric carcinoma examin substanti potenti role sepras gastric carcinoma invas method examin sepras express human gastric carcinoma rt-pcr western immunoblot analysi immunohistochemistri gelatin zymographi result immunoblot analysi us mab direct sepras show carcinoma tissu case gastric cancer express dimer form sepras normal counterpart gelatin zymographi confirm isol sepras exhibit gelatin-degrad activ activ sepras-express carcinoma tissu found scirrhou type type gastric carcinoma rt-pcr analysi show sepras mrna present carcinoma tissu normal tissu immunohistochem sepras mainli locat gastric carcinoma cell weakli stromal cell microvessel endotheli cell tumor nest none normal cell conclus studi show uniqu express local sepras tumor stromal cell human gastric carcinoma normal tissu suggest role sepras invas metastat progress gastric carcinoma
object observ influenc chemotherapi switch th1/th2 cytokin stomach cancer patient method th1/th2 cytokin gene express peripher blood mononuclear cell stomach cancer patient befor chemotherapi detect rt-pcr result express th2 cytokin domin patient befor chemotherapi domin becam mark chemotherapi conclus immun deviat th2 predomin stomach cancer patient tendenc becom revers chemotherapi
